Theranostics in primary care: pharmacogenomics tests and beyond
- 1 November 2012
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 12 (8), 841-855
- https://doi.org/10.1586/erm.12.115
Abstract
Theranostics represents a broadening in the scope of personalized medicine to include companion diagnostics for health interventions ranging from drugs to vaccines, as well as individual susceptibility to disease. Surprisingly, in the course of this broadening of personalized medicine discourse, relatively little attention has been paid to primary care (as compared with tertiary healthcare settings) despite its vast patient population and being a crucial entry point to health services. Recent advances in pharmacogenomics (PGx), a classical theranostics application whereby genotyping and/or gene expression-based tests are used for targeted or optimal therapy, revealed new opportunities to characterize more precisely human genomic variation and the ways in which it contributes to person-to-person and population variations in drug response. In the immediate foreseeable future, the primary-care physicians are expected to play an ever increasing crucial role in PGx-based prescribing in order to reduce the rates of adverse drug events and improve drug efficacy, yet PGx testing in primary care remains limited. In this article, the authors review the advances in PGx applications, the barriers for their adoption in the clinic from a primary care point of view and the efforts that are being undertaken to move PGx forward in this hitherto neglected application context of theranostic medicine. Finally, the authors propose several salient recommendations, including a 5-year forecast, to accelerate the current convergence between PGx and primary care.Keywords
This publication has 81 references indexed in Scilit:
- CYP2C19 and Clopidogrel Response: More Than Validation in the Real WorldClinical Pharmacology & Therapeutics, 2012
- The Path to Personalized MedicineNew England Journal of Medicine, 2010
- Pharmacogenetics in breast cancer: focus on hormone therapy, taxanes, trastuzumab and bevacizumabExpert Opinion on Investigational Drugs, 2010
- DNA, Drugs and Chariots: On a Decade of Pharmacogenomics at the US FDAPharmacogenomics, 2010
- Évaluation et validation des tests diagnostiques dans le cadre du ciblage thérapeutiqueTherapies, 2009
- Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 2007
- Pharmacogenetics, Adverse Drug Reactions and Public HealthPublic Health Genomics, 2006
- Quo vadis personalized medicine?Personalized Medicine, 2004
- Pharmacogenetics and pharmacogenomics: are they still promising?Pharmacological Research, 2004
- Policy relevant determinants of health: an international perspectiveHealth Policy, 2002